SYDNEY, Australia, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the
“Company”) is pleased to announce that it has received a €876,635 (A$1,306,266) cash rebate from the French Government under its
Crédit d’Impôt Recherche scheme (CIR). Through CIR the French government reimburses companies, whether French or international, for
undertaking research and development activity in France by up to 30%.
Prima BioMed qualifies to receive CIR credits via its subsidiary Immutep due to R&D conducted in its laboratory
at Châtenay-Malabry in southwestern Paris in the 2016 calendar year. Prima is currently working on new products in addition to the
development work related to lead compound IMP321, in both cancer treatment and other settings.
The additional funding will be used for the development of its IMP321 clinical trial programs in Europe and
Australia.
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further
information please visit www.primabiomed.com.au.
For further information please contact: U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; mbeck@troutgroup.com Australian Investors/Media: Matthew Gregorowski, Citadel-MAGNUS +61 2 8234 0105; mgregorowski@citadelmagnus.com
